Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the RAS, ICBFM SB RAS (Russian: Институт химической биологии и фундаментальной медицины СО РАН, ИХБФМ СО РАН) is a research institute in Novosibirsk, Russia. It was founded in 1984.
| Established | 1984 |
|---|---|
| Director | Dmitry Pyshny |
| Owner | Siberian Branch of the Russian Academy of Sciences |
| Address | Lavrentyev Prospekt 8, Novosibirsk, 630090, Russia |
| Location | , Russia |
| Website | www |
History edit
The Institute of Chemical Biology and Fundamental Medicine (formerly the Novosibirsk Institute of Bioorganic Chemistry) was founded on 1 April 1984.[1]
Scientific activity edit
Creation of gene-targeted biological preparations, developments in the field of gene therapy, the study of physical and chemical processes of transmission and preservation of hereditary information.[1]
Test system for detection of SARS-CoV-2 Omicron variant edit
At the end of 2021, the staff of the ICBFM SB RAS, together with scientists from Saint Petersburg, created a test system that simultaneously detects the presence of the genetic material of the coronavirus and determines whether it belongs to the omicron strain.[1]
Method for inactivating the CRISPR/Cas9 genome editing system at a specific point in time edit
The CRISPR/Cas9 genome editing was discovered by molecular biologists Jennifer Doudna (United States) and Emmanuelle Charpentier (France), thanks to which they received the Nobel Prize.[2]
Scientists at the ICBFM SB RAS have developed a method to inactivate the CRISPR/Cas9 genome editing system at a specific point in time.[2]
In 2022, the institute received a patent for the invention – Modified guide RNA which has the ability to inactivate the CRISPR/Cas9 genome editing system, and method for obtaining it (Модифицированная направляющая РНК, обладающая способностью инактивировать систему редактирования генома CRISPR/Cas9, и способ ее получения).[2]